Stiris Research Inc. Announces First Site Initiated in Study Using Artificial Intelligence (AI) in Patients with Depression
Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces the first site initiated in a phase IIb study utilizing artificial intelligence (AI) for clinical diagnosis of Depression.
“Stiris is pleased to announce that patients are now one step closer to accessing a first-in-world technology to help treat major depressive disorder. The first sites have been activated and are ready to recruit patients into the clinical trial, paving the way for advances in therapies combining artificial intelligence and therapeutics with the aim of improving the lives of those suffering from this disorder,” said Lisa Discepola, Managing Director, Clinical Operations.
Clinical depression is a complex mood disorder caused by various factors, including genetic predisposition, personality, stress and brain chemistry. Treatments include psychoeducation, psychotherapy, pharmacotherapy, and brain stimulation therapies (electroconvulsive therapy, transcranial magnetic stimulation, and magnetic seizure therapy). Depression can affect anyone: children, adolescents, young adults, middle-aged adults and older people. 20% of adults will have suffered from depression at some point in their lifetimes. Depression may be caused by one factor alone or a combination of factors including biological, psychological and environmental (linked to social or family environment) factors.
About Stiris Research
Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.
For more information, please contact: